Market Closed -
OTC Markets
13:56:51 2024-05-20 EDT
|
5-day change
|
1st Jan Change
|
0.000001
USD
|
-99.00%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
0.2391
|
0.0445
|
0.0581
|
0.9112
|
0.2742
|
0.241
|
Enterprise Value (EV)
1 |
2.705
|
2.641
|
2.88
|
2.385
|
0.0772
|
0.546
|
P/E ratio
|
-
|
-
|
-
|
-0.04
x
|
-0.4
x
|
-0.23
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-0.81
x
|
-3.75
x
|
-5.03
x
|
-5.01
x
|
-
|
-
|
EV / FCF
|
-32.5
x
|
-2.84
x
|
20.6
x
|
0.49
x
|
-0.01
x
|
-0.79
x
|
FCF Yield
|
-3.08%
|
-35.3%
|
4.85%
|
205%
|
-8,155%
|
-127%
|
Price to Book
|
-
|
-
|
-
|
-0.09
x
|
-0.06
x
|
-0.05
x
|
Nbr of stocks (in thousands)
|
0.17
|
0.19
|
5.06
|
2,000
|
10,309
|
32,133
|
Reference price
2 |
1,406
|
230.6
|
11.48
|
0.4556
|
0.0266
|
0.007500
|
Announcement Date
|
19-04-26
|
19-08-06
|
20-05-14
|
21-03-31
|
22-03-31
|
23-03-31
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-3.32
|
-0.705
|
-0.573
|
-0.476
|
-
|
-
|
EBIT
1 |
-3.36
|
-0.724
|
-0.609
|
-0.512
|
-1.022
|
-0.664
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-11.1
|
-0.012
|
-0.934
|
-6.295
|
2.698
|
-1.02
|
Net income
1 |
-11.1
|
-0.012
|
-0.934
|
-6.295
|
2.698
|
-1.02
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-11.00
|
-0.0663
|
-0.0321
|
Free Cash Flow
1 |
-0.0832
|
-0.9312
|
0.1398
|
4.899
|
-6.298
|
-0.6911
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-04-26
|
19-08-06
|
20-05-14
|
21-03-31
|
22-03-31
|
23-03-31
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
2.47
|
2.6
|
2.82
|
1.47
|
-
|
0.31
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
0.2
|
-
|
Leverage (Debt/EBITDA)
|
-0.7428
x
|
-3.682
x
|
-4.925
x
|
-3.097
x
|
-
|
-
|
Free Cash Flow
1 |
-0.08
|
-0.93
|
0.14
|
4.9
|
-6.3
|
-0.69
|
ROE (net income / shareholders' equity)
|
228%
|
0.14%
|
11%
|
59.3%
|
-30.8%
|
19.9%
|
ROA (Net income/ Total Assets)
|
-523%
|
-208%
|
-196%
|
-150%
|
-114%
|
-115%
|
Assets
1 |
2.122
|
0.005768
|
0.4773
|
4.2
|
-2.363
|
0.8848
|
Book Value Per Share
|
-
|
-
|
-
|
-5.050
|
-0.4300
|
-0.1600
|
Cash Flow per Share
|
-
|
-
|
-
|
0.1600
|
0.0600
|
0
|
Capex
1 |
0
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-04-26
|
19-08-06
|
20-05-14
|
21-03-31
|
22-03-31
|
23-03-31
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 32 | | +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.57B | | +3.23% | 22.82B | | -10.44% | 18.19B | | -41.74% | 16.54B | | -13.31% | 16.5B | | +2.44% | 13.39B | | +27.89% | 11.1B |
Bio Therapeutic Drugs
|